Foghorn Therapeutics Inc. Quarterly Income Tax Expense (Benefit) in USD from Q1 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Foghorn Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2022 to Q3 2024.
  • Foghorn Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $0.000, a 100% decline year-over-year.
  • Foghorn Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $1.99M, a 11.3% decline year-over-year.
  • Foghorn Therapeutics Inc. annual Income Tax Expense (Benefit) for 2023 was $4.23M.
  • Foghorn Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $0.000.
  • Foghorn Therapeutics Inc. annual Income Tax Expense (Benefit) for 2020 was $0.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.99M $0 -$738K -100% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $2.72M $0 -$942K -100% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $3.67M $0 -$560K -100% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $4.23M $1.99M +$1.99M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 $2.24M $738K +$738K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $1.5M $942K +$942K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $560K $560K +$560K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $0 $0 Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $0 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.